CooperVision received the U.S. Food and Drug Administration (FDA) approval for their contact lenses MiSight®1 Day. Disposable and for daily repalcement, this lenses are the fisrt and only product approved by FDA, that clinically proved to be capable of delay the progression of myopia when prescripted for children between 8 and 12 years old.
“It´s not an overstatment when we stress about the importance and potencial impact of this historical decision for the sight of our children, specially considering the increased severity and prevalence of myopia in the United States and around the world. Eye care professionals that choose to precribe this innovative product will improve the life quality and vision health of many children”, said Daniel G. McBride, president of CooperVision.
Learn more in the next issue.
